Multiple SclerosisGAIT-MSNCT07388992
Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis
An observational study of Multiple Sclerosis and Healthy Adult, run by SYSNAV at 1 site in France.
Trial summary
The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS) Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Multiple Sclerosis, Healthy Adult
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- 16 Mar 2026to Jun 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with MS will be recruited from the CHU Lille. Patients will be informed of this study by the Investigator during routine follow-up visits. The Investigator will also connect with local patient organizations and share a flyer. This flyer will also be displayed within the Neurology and Neurological Rehabilitation departments of the hospital and diffused to the hospital staff.
Who may be able to join
- For people living with multiple sclerosis (pwMS):
- Age at inclusion between =18 and =65 years old
- Signed informed consent and ability to comply with study and follow-up.
- Confirmed MS diagnosis according to McDonald criteria (2017)
- Expanded Disability Status Scale EDSS = 6
- Stable treatment for 2 months before inclusion (for both disease modifying and symptomatic therapies)
Show all 13Show fewer
- Ability and willingness to participate in and comply with all study procedures defined in the protocol
- Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category
- For Healthy volunteers :
- Age at inclusion between =18 and =65 years old
- Signed informed consent and ability to comply with study and follow-up.
- Ability and willingness to participate in and comply with all study procedures defined in the protocol
- Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category
Who cannot join
- For pwMS:
- Participants with a relapse within the past 3 months before the inclusion
- Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator
- Past or present pathology other than MS or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator
- Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.
- For healthy volunteers (HV):
Show all 9Show fewer
- Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator
- Past or present pathology or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator
- Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Lille
Lille
Sophie Corbinau, +33 (0)3.20.44.59.62 ext. 30768, sophie.corbinau@chu-lille.fr
Patrick Vermersch
About this study
The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS)
- Conditions
- Multiple Sclerosis, Healthy Adult
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| people living with Multiple Sclerosis | Not described | |
| Healthy Adult | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
description of ambulation pattern in controlled environment in people living with multiple sclerosis (pwMS) with different disease severities
Measurement of daily life-like activity movements by Optical Motion Capture, pressure sensitive walkway and wearable sensors
Measured: enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2026
- Study start16 Mar 2026
- Primary completionJun 2026 (estimated)
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SYSNAV
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Patrick Vermersch, Principal investigator, CHU Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07388992
- Sponsor's protocol ID
- PR5030-119
- Other IDs
- 2025-A02511-48
- Acronym
- GAIT-MS
- Status last verified
- Mar 2026
- First submitted
- 28 Jan 2026
- Last updated
- 23 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT07388992
- Acronym / sponsor ID
- GAIT-MS / PR5030-119
- Conditions
- Multiple Sclerosis, Healthy Adult
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- SYSNAVIndustry (pharma, biotech, devices)
- Study start
- 16 Mar 2026 (actual)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Jun 2026 (estimated)
- First posted
- 5 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS)
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| people living with Multiple Sclerosis | – | – |
| Healthy Adult | – | – |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with MS will be recruited from the CHU Lille. Patients will be informed of this study by the Investigator during routine follow-up visits. The Investigator will also connect with local patient organizations and share a flyer. This flyer will also be displayed within the Neurology and Neurological Rehabilitation departments of the hospital and diffused to the hospital staff.
Key inclusion criteria (13 listed)
- Age at inclusion between =18 and =65 years old
- Signed informed consent and ability to comply with study and follow-up.
- Confirmed MS diagnosis according to McDonald criteria (2017)
- Expanded Disability Status Scale EDSS = 6
- Stable treatment for 2 months before inclusion (for both disease modifying and symptomatic therapies)
Key exclusion criteria (9 listed)
- Participants with a relapse within the past 3 months before the inclusion
- Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator
- Past or present pathology other than MS or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator
- Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.
- Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
description of ambulation pattern in controlled environment in people living with multiple sclerosis (pwMS) with different disease severities
Time frame: enrollment
Measurement of daily life-like activity movements by Optical Motion Capture, pressure sensitive walkway and wearable sensors
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2026.
Related trials for Multiple Sclerosis
Active, not recruitingPhase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis (RMS)
RecruitingObservational study
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis, Multiple Sclerosis
RecruitingObservational study
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
RecruitingPhase 2
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Primary Progressive Multiple Sclerosis, Primary Progressive MS
RecruitingPhase 4
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Patrick Vermersch principal investigator
CHU Lille
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis and Healthy Adult, run by SYSNAV at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ferial Toumi (+33 2 78 00 10 98, ferial.toumi@sysnav.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
description of ambulation pattern in controlled environment in people living with multiple sclerosis (pwMS) with different disease severities (time frame: enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2026.